Novo Nordisk Biotech Fund

Corporate Venture Capital Fund



Novo Nordisk Biotech Fund is Novo Nordisk’s internal Corporate Venture Capital Fund, responsible for equity investments biotechnology companies.

Investments are made globally in companies that focus on discovering or developing innovative therapies or technologies that help shape Novo Nordisk’s future; but are too distant to engage in a formalized collaboration or license at the present stage.
Investments are made with the objective of generating both strategic and financial return to Novo Nordisk. Investments are made on a ‘stand-alone-basis’ or as part of the terms of a licensing and/or collaboration agreement with Novo Nordisk. Where feasible, we seek to gain rights and privileges to Novo Nordisk as part of the terms of the investment.

Established in 2001, Novo Nordisk Biotech Fund has invested more than USD 60 million in biotechnology companies. Novo Nordisk Biotech Fund typically invests USD 2 to 8 million per company per financing round.

Investment focus areas

 Early stage as well as later stage companies, operating within the areas of:
  • Diabetes
  • Inflammation
  • Obesity
  • Haemostasis
  • Protein Delivery Systems and Devices
  • Enabling Technologies

To the portfolio companies, Novo Nordisk Biotech Fund seeeks to offer

  • Venture capital funding. Early to late stage
  • Strong Commitment
  • Access to Novo Nordisk’s R&D competencies

Contact

Johannes Jensen
Vice President, Novo Nordisk Biotech Fund
Direct Phone: ++45 4442 4922

Further information
For further information and contact information, please go to Novo Nordisk Biotech Fund’s web site: www.biotechfund.novonordisk.com